Early  ||| S:0 E:6 ||| JJ
treatment  ||| S:6 E:16 ||| NN
of  ||| S:16 E:19 ||| IN
multiple  ||| S:19 E:28 ||| JJ
sclerosis ||| S:28 E:37 ||| NN
:  ||| S:37 E:39 ||| :
a  ||| S:39 E:41 ||| DT
Latin  ||| S:41 E:47 ||| JJ
American  ||| S:47 E:56 ||| JJ
experts  ||| S:56 E:64 ||| NNS
meeting  ||| S:64 E:72 ||| NN
Patients  ||| S:72 E:81 ||| NNS
with  ||| S:81 E:86 ||| IN
clinically  ||| S:86 E:97 ||| JJ
isolated  ||| S:97 E:106 ||| JJ
syndrome  ||| S:106 E:115 ||| NN
( ||| S:115 E:116 ||| -LRB-
CIS ||| S:116 E:119 ||| NNP
)  ||| S:119 E:121 ||| -RRB-
by  ||| S:121 E:124 ||| IN
definition  ||| S:124 E:135 ||| NN
do  ||| S:135 E:138 ||| VBP
not  ||| S:138 E:142 ||| RB
have  ||| S:142 E:147 ||| VB
multiple  ||| S:147 E:156 ||| JJ
sclerosis  ||| S:156 E:166 ||| NNS
( ||| S:166 E:167 ||| -LRB-
MS ||| S:167 E:169 ||| NNP
)  ||| S:169 E:171 ||| -RRB-
but  ||| S:171 E:175 ||| CC
are  ||| S:175 E:179 ||| VBP
at  ||| S:179 E:182 ||| IN
risk  ||| S:182 E:187 ||| NN
of  ||| S:187 E:190 ||| IN
developing  ||| S:190 E:201 ||| VBG
it ||| S:201 E:203 ||| PRP
.  ||| S:203 E:205 ||| .
While  ||| S:205 E:211 ||| IN
studies  ||| S:211 E:219 ||| NNS
show  ||| S:219 E:224 ||| VBP
earlier  ||| S:224 E:232 ||| RBR
immunomodulating  ||| S:232 E:249 ||| JJ
drug  ||| S:249 E:254 ||| NN
use  ||| S:254 E:258 ||| NN
is  ||| S:258 E:261 ||| VBZ
effective ||| S:261 E:270 ||| JJ
,  ||| S:270 E:272 ||| ,
treatment  ||| S:272 E:282 ||| NN
must  ||| S:282 E:287 ||| MD
consider  ||| S:287 E:296 ||| VB
likely  ||| S:296 E:303 ||| JJ
patient  ||| S:303 E:311 ||| NN
prognosis ||| S:311 E:320 ||| NN
.  ||| S:320 E:322 ||| .
In  ||| S:322 E:325 ||| IN
this  ||| S:325 E:330 ||| DT
paper  ||| S:330 E:336 ||| NN
we  ||| S:336 E:339 ||| PRP
review  ||| S:339 E:346 ||| VBP
current  ||| S:346 E:354 ||| JJ
diagnosis ||| S:354 E:363 ||| NN
,  ||| S:363 E:365 ||| ,
prognosis ||| S:365 E:374 ||| NN
,  ||| S:374 E:376 ||| ,
and  ||| S:376 E:380 ||| CC
treatment  ||| S:380 E:390 ||| NN
literature  ||| S:390 E:401 ||| NN
for  ||| S:401 E:405 ||| IN
patients  ||| S:405 E:414 ||| NNS
with  ||| S:414 E:419 ||| IN
CIS  ||| S:419 E:423 ||| NNP
within  ||| S:423 E:430 ||| IN
Latin  ||| S:430 E:436 ||| NNP
American  ||| S:436 E:445 ||| NNP
clinical  ||| S:445 E:454 ||| JJ
settings ||| S:454 E:462 ||| NNS
.  ||| S:462 E:464 ||| .
Latin  ||| S:464 E:470 ||| NNP
American  ||| S:470 E:479 ||| NNP
MS  ||| S:479 E:482 ||| NNP
experts ||| S:482 E:489 ||| NNS
,  ||| S:489 E:491 ||| ,
convened  ||| S:491 E:500 ||| VBN
by  ||| S:500 E:503 ||| IN
ACINDES  ||| S:503 E:511 ||| NNP
( ||| S:511 E:512 ||| -LRB-
The  ||| S:512 E:516 ||| DT
Civil  ||| S:516 E:522 ||| NNP
Association  ||| S:522 E:534 ||| NNP
for  ||| S:534 E:538 ||| IN
Research  ||| S:538 E:547 ||| NNP
and  ||| S:547 E:551 ||| CC
Development  ||| S:551 E:563 ||| NNP
in  ||| S:563 E:566 ||| IN
Health ||| S:566 E:572 ||| NNP
) ||| S:572 E:573 ||| -RRB-
,  ||| S:573 E:575 ||| ,
reviewed  ||| S:575 E:584 ||| VBN
current  ||| S:584 E:592 ||| JJ
CIS  ||| S:592 E:596 ||| NNP
( ||| S:596 E:597 ||| -LRB-
and  ||| S:597 E:601 ||| CC
early  ||| S:601 E:607 ||| JJ
MS ||| S:607 E:609 ||| NNP
)  ||| S:609 E:611 ||| -RRB-
literature  ||| S:611 E:622 ||| NN
and  ||| S:622 E:626 ||| CC
drew  ||| S:626 E:631 ||| VBD
consensus  ||| S:631 E:641 ||| NN
conclusions ||| S:641 E:652 ||| NNS
.  ||| S:652 E:654 ||| .
Three  ||| S:654 E:660 ||| CD
subgroups  ||| S:660 E:670 ||| NNS
addressed  ||| S:670 E:680 ||| VBD
separate  ||| S:680 E:689 ||| JJ
questionnaires  ||| S:689 E:704 ||| NN
on  ||| S:704 E:707 ||| IN
CIS  ||| S:707 E:711 ||| NNP
issues ||| S:711 E:717 ||| NNS
:  ||| S:717 E:719 ||| :
prognosis ||| S:719 E:728 ||| CD
,  ||| S:728 E:730 ||| ,
diagnosis ||| S:730 E:739 ||| NN
,  ||| S:739 E:741 ||| ,
and  ||| S:741 E:745 ||| CC
treatment ||| S:745 E:754 ||| NN
.  ||| S:754 E:756 ||| .
MRI  ||| S:756 E:760 ||| NNP
can  ||| S:760 E:764 ||| MD
contribute  ||| S:764 E:775 ||| VB
to  ||| S:775 E:778 ||| TO
predicting  ||| S:778 E:789 ||| VBG
MS  ||| S:789 E:792 ||| NNP
risk  ||| S:792 E:797 ||| NN
in  ||| S:797 E:800 ||| IN
patients  ||| S:800 E:809 ||| NNS
with  ||| S:809 E:814 ||| IN
CIS ||| S:814 E:817 ||| NNP
;  ||| S:817 E:819 ||| :
in  ||| S:819 E:822 ||| IN
Latin  ||| S:822 E:828 ||| NNP
America ||| S:828 E:835 ||| NNP
,  ||| S:835 E:837 ||| ,
investigation  ||| S:837 E:851 ||| NN
of  ||| S:851 E:854 ||| IN
haplotype  ||| S:854 E:864 ||| JJ
presence  ||| S:864 E:873 ||| NN
associated  ||| S:873 E:884 ||| VBN
with  ||| S:884 E:889 ||| IN
CIS  ||| S:889 E:893 ||| NNP
would  ||| S:893 E:899 ||| MD
be  ||| S:899 E:902 ||| VB
appropriate ||| S:902 E:913 ||| JJ
.  ||| S:913 E:915 ||| .
McDonald ||| S:915 E:923 ||| NNP
's  ||| S:923 E:926 ||| POS
criteria  ||| S:926 E:935 ||| NNS
and  ||| S:935 E:939 ||| CC
subsequent  ||| S:939 E:950 ||| JJ
revisions  ||| S:950 E:960 ||| NNS
enable  ||| S:960 E:967 ||| VBP
earlier ||| S:967 E:974 ||| RBR
,  ||| S:974 E:976 ||| ,
more  ||| S:976 E:981 ||| RBR
accurate  ||| S:981 E:990 ||| JJ
MS  ||| S:990 E:993 ||| NNP
diagnosis ||| S:993 E:1002 ||| NN
.  ||| S:1002 E:1004 ||| .
Type  ||| S:1004 E:1009 ||| NN
A  ||| S:1009 E:1011 ||| DT
evidence  ||| S:1011 E:1020 ||| NN
exists  ||| S:1020 E:1027 ||| VBZ
supporting  ||| S:1027 E:1038 ||| VBG
all  ||| S:1038 E:1042 ||| DT
leading  ||| S:1042 E:1050 ||| JJ
immunomodulating  ||| S:1050 E:1067 ||| JJ
MS  ||| S:1067 E:1070 ||| NN
drugs  ||| S:1070 E:1076 ||| NNS
for  ||| S:1076 E:1080 ||| IN
effective  ||| S:1080 E:1090 ||| JJ
treatment  ||| S:1090 E:1100 ||| NN
of  ||| S:1100 E:1103 ||| IN
CIS  ||| S:1103 E:1107 ||| NNP
with  ||| S:1107 E:1112 ||| IN
a  ||| S:1112 E:1114 ||| DT
high  ||| S:1114 E:1119 ||| JJ
risk  ||| S:1119 E:1124 ||| NN
of  ||| S:1124 E:1127 ||| IN
conversion  ||| S:1127 E:1138 ||| NN
to  ||| S:1138 E:1141 ||| TO
MS ||| S:1141 E:1143 ||| NNP
.  ||| S:1143 E:1145 ||| .
In  ||| S:1145 E:1148 ||| IN
conclusion ||| S:1148 E:1158 ||| NN
,  ||| S:1158 E:1160 ||| ,
patients  ||| S:1160 E:1169 ||| NNS
with  ||| S:1169 E:1174 ||| IN
CIS  ||| S:1174 E:1178 ||| NNP
are  ||| S:1178 E:1182 ||| VBP
usually  ||| S:1182 E:1190 ||| RB
young ||| S:1190 E:1195 ||| JJ
,  ||| S:1195 E:1197 ||| ,
with  ||| S:1197 E:1202 ||| IN
often-limited  ||| S:1202 E:1216 ||| JJ
symptomatic  ||| S:1216 E:1228 ||| JJ
manifestations ||| S:1228 E:1242 ||| NNS
,  ||| S:1242 E:1244 ||| ,
and  ||| S:1244 E:1248 ||| CC
must  ||| S:1248 E:1253 ||| MD
be  ||| S:1253 E:1256 ||| VB
adequately  ||| S:1256 E:1267 ||| RB
prepared  ||| S:1267 E:1276 ||| VBN
to  ||| S:1276 E:1279 ||| TO
receive  ||| S:1279 E:1287 ||| VB
preventive  ||| S:1287 E:1298 ||| JJ
treatment ||| S:1298 E:1307 ||| NN
.  ||| S:1307 E:1309 ||| .
This  ||| S:1309 E:1314 ||| DT
consensus  ||| S:1314 E:1324 ||| NN
review  ||| S:1324 E:1331 ||| NN
should  ||| S:1331 E:1338 ||| MD
contribute  ||| S:1338 E:1349 ||| VB
to  ||| S:1349 E:1352 ||| TO
the  ||| S:1352 E:1356 ||| DT
dialogue  ||| S:1356 E:1365 ||| NN
between  ||| S:1365 E:1373 ||| IN
physicians  ||| S:1373 E:1384 ||| NNS
and  ||| S:1384 E:1388 ||| CC
patients ||| S:1388 E:1396 ||| NNS
.  ||| S:1396 E:1398 ||| .
